Nkarta/$NKTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nkarta
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Ticker
$NKTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
109
ISIN
US65487U1088
Website
Nkarta Metrics
BasicAdvanced
$129M
-
-$1.51
0.81
-
Price and volume
Market cap
$129M
Beta
0.81
52-week high
$8.23
52-week low
$1.31
Average daily volume
448K
Financial strength
Current ratio
14.478
Quick ratio
14.284
Long term debt to equity
19.261
Total debt to equity
20.832
Profitability
EBITDA (TTM)
-117.7
Management effectiveness
Return on assets (TTM)
-15.14%
Return on equity (TTM)
-26.10%
Valuation
Price to book
0.34
Price to tangible book (TTM)
0.34
Price to free cash flow (TTM)
-1.27
Free cash flow yield (TTM)
-78.72%
Free cash flow per share (TTM)
-143.27%
Growth
Earnings per share change (TTM)
-35.73%
3-year earnings per share growth (CAGR)
-18.75%
What the Analysts think about Nkarta
Analyst ratings (Buy, Hold, Sell) for Nkarta stock.
Nkarta Financial Performance
Revenues and expenses
Nkarta Earnings Performance
Company profitability
Nkarta News
AllArticlesVideos
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
GlobeNewsWire·2 weeks ago
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space
Benzinga·1 month ago
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nkarta stock?
Nkarta (NKTX) has a market cap of $129M as of June 21, 2025.
What is the P/E ratio for Nkarta stock?
The price to earnings (P/E) ratio for Nkarta (NKTX) stock is 0 as of June 21, 2025.
Does Nkarta stock pay dividends?
No, Nkarta (NKTX) stock does not pay dividends to its shareholders as of June 21, 2025.
When is the next Nkarta dividend payment date?
Nkarta (NKTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Nkarta?
Nkarta (NKTX) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.